DUSP1 and glioblastoma: Taken together, our data suggest that treatment of GBM cells with CP-673451 inhibits PDGF-Rα/β, inducing the upregulation of phosphatase DUSP1, which reduces levels of phosphorylated p38MAPK, ultimately leading to the onset of neuron-like differentiation and consecutive neurite-like process formation (Fig. 8) [32].